Shanghai held a symposium on the third round of belt quantity procurement to expand the variety of trumpet!

After the first round of 4 + 7 pilot projects and the second round of national expansion, the third round of belt procurement and expansion has rapidly entered the preparatory stage On November 20, the executive meeting of the State Council released key policy signals, further promoted the centralized purchase and use of drugs, and accelerated the inclusion of more varieties for centralized purchase On the same day, Hebei Province, which is independent of "only two" in the centralized procurement, was the first to carry out centralized procurement for 15 drugs for hypertension and diabetes Today, Liancai held a symposium on centralized procurement in Shanghai The third tire purchase and variety expansion has sounded the clarion call! On November 27, less than a year before the opening of the first round of "12.6" belt quantity procurement, after the second round of belt quantity procurement expansion to the fierce national competition, the third round of belt quantity procurement expansion finally entered the stage of formal preparation Shanghai, 27, and last year's "12.6" first round with the same amount of procurement bid opening day, a day of cold rain At 2:00 p.m in the peony Hall of Longbai hotel in Shanghai, associated procurement held a corporate Symposium on centralized drug procurement to find out the varieties for the third round of belt quantity procurement in advance E drug managers learned on the spot that eight enterprises, including Merck, Bayer, Shiyao, Sanofi, Kelen, Hengrui, Zhengda Tianqing, Qilu, participated in the corporate symposium, and rdpac and other associations also participated in the discussion According to the on-site introduction of the relevant person in charge, this symposium is to collect the opinions of the enterprises for the new round of belt quantity procurement bidding, so as to form a complete list of the third round of belt quantity procurement varieties, but the specific varieties involved will not be discussed on the site, and all the enterprises involved in the third round of belt quantity procurement varieties will be convened next week to hold a more comprehensive Symposium From the signal of all levels, the horn of the third wheel belt quantity purchase has sounded, and a wider range of varieties will enter the belt quantity purchase On November 20, the executive meeting of the State Council released important policy signals to further promote the centralized purchase and use of drugs when it planned to further deepen the focus of medical and health system reform From the perspective of national high-level, it sets the overall policy tone for the purchase and expansion of the third wheel belt quantity In particular, the meeting stressed that the scope of centralized procurement and use of drug varieties should be expanded, and priority should be given to the varieties with large price difference between the original research drugs and generic drugs, as well as the essential drugs through the consistency evaluation of quality and efficacy of generic drugs, etc into the centralized procurement to promote the reduction of drug price and quality with volume procurement In addition to "expanding varieties", it also set goals for some key policy details For the problems of stable supply and quality safety of centrally purchased drugs that are of great concern to the industry, it is required to establish an emergency reserve, inventory and capacity reporting system for winning manufacturers, strengthen the sampling inspection of winning drugs, and implement the market clearing system We will build a drug traceability system, take the lead in realizing "one thing, one code" for vaccines and drugs purchased and used centrally by the state by the end of next year, which can be independently inspected by the public It is worth noting that in the guiding opinions on the construction of drug information traceability system issued by the State Food and Drug Administration on November 1, 2018, only the key products such as vaccines, narcotic drugs, psychotropic drugs, drug precursor chemicals, blood products, etc should take the lead in establishing the drug information traceability system On September 11, 2019, the State Food and Drug Administration issued a draft for comments on five standards for the construction of drug information traceability system, indicating that the construction of drug information traceability system has entered a key policy preparation stage At the State Council meeting, it was specially made clear that the national centralized purchase and use of drugs became the first pilot variety of "one thing, one code", which means that in order to ensure the stable supply and quality safety of centralized purchase of drugs, the first two batches of 25 varieties with volume purchase and the third batch of products with volume purchase to be implemented will become the first batch of enterprises "eating crabs" in the drug information traceability system The meeting also defined a clear policy direction for medical institutions and medical insurance payment incentives, which are crucial to the centralized mining area "Reward and punishment" shall be given to medical institutions for purchasing drugs with quantity To punish the unreasonable use of drugs, it is required to formulate and implement the national drug administration measures We will promote medical institutions to first use national essential drugs and Medicare listed drugs We will strengthen the management of pharmaceutical affairs in hospitals and investigate and deal with irrational drug use in accordance with the law Establish and improve the regulatory mechanism for the normalization of drug prices For rational drug use, there is a "prize" It is required to explore the optimization of medical service price in a safe and orderly pilot under the premise of not increasing the burden of patients That is to say, it is required to use the money saved by purchasing with volume to solve the incentive promotion of medical institutions and medical personnel In addition, it also requires the reform of medical insurance payment, the same general name to implement the same payment standards, and explore more efficient payment methods for drugs It is worth noting that on the day when the executive meeting of the State Council was held to set the general policy tone for the third round of belt quantity procurement, Hebei Province, as the only two provinces that independently carry out belt quantity procurement, took the lead in carrying out belt quantity procurement for 15 outpatients of hypertension and diabetes Hebei province carries out volume purchase for outpatient drugs of "two diseases", carries out drug bidding in the form of open ceiling price, and gives all market shares to the winning enterprises For the varieties of the three enterprises that have not been invited for conformity evaluation, the products that have not been invited for conformity evaluation are allowed to participate in the bidding According to the calculation of the ceiling price, the bidding for drugs used in outpatient clinics of "two diseases" in Hebei Province involves more than 500 million yuan of purchase plates, among which there are many large varieties with a total purchase amount of more than 100 million yuan, such as acarbose Although many "two diseases" drugs are not mainly used in outpatient clinics of hospitals, but in the third terminal retail market, considerable committed purchase amount and 100% market share are used in collection Purchase is still very attractive for enterprises.